Boston, MA 01/06/2013 (wallstreetpr) – American biotechnology research and pharmaceutical firm Inovio Pharmaceuticals Inc (NYSEMKT:INO), which has seen tremendous response for its key and revolutionary DNA vaccines – the INO-5150 aimed for the treatment of prostate cancer and the INO-1800 for hepatitis B type, has been ranked one of the most promising biotechnology firms of 2013. The pharmaceutical player recently saw its share value rise again significantly in mid-December, although Inovio stocks have been bobbing up and down over the past three months.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), which is currently intent on the creation and manufacture of a new generation of DNA-based vaccines, figured a week ago among 2013’s biggest health care performers with stocks climbing by 32%. This is owing to various contributing factors like Inovio’s recent DNA-oriented and cancer-oriented innovations, largely the synthetic DNA vaccines designed and targeted for cervical dysplasia, which have evoked positive hype and optimism and triggered significant capital investments from various institutional investors.
Furthermore, Inovio Pharmaceuticals Inc (NYSEMKT:INO), sees a winner in its collaboration with Roche in the niche and mostly uncharted territory of preventive cancer research and immunotherapy, which is expected to bear good fruit in the future, though Inovio would necessarily need time to mass manufacture and deploy the vaccines and drugs in markets for common use. The progressive pharmaceutical player has seen good research success in the past, its recent loss-making third quarter notwithstanding.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s DNA innovations and the resultant positive impact on shareholder sentiments and stock value date back to its August 2013 announcement of the malaria DNA vaccine SynCon that showed encouraging immunity results in tests. Subsequently, Inovio struck up the ambitious alliance with Roche for the joint development and manufacture of its DNA-based vaccines INO-5150 aimed for the treatment of prostate cancer and the INO-1800 for hepatitis B type.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares, which have grown almost 20% over the last month, closed January 3 trading on NYSE’s small capital firms index (NYSEMKT) at $2.50, down 12% from the previous $2.87, while after-hours trading figures surged slightly to $2.54.
